Bayer logo
US MEDICAL AFFAIRS
Contact Us icon

Publications

Publications

Home / Publications 

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of stroke prevention.

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated January 2026.

Types of Enhancements Available

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 44    

Filtered results: 44

Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events

Yassen A, et al. CPT: Pharmacometrics Syst Pharmacol. 2025. Online ahead of print

Yassen A, Kanefendt F, Zisowsky J, et al.,
READ
EMAIL

Location, size, and risk factors of incident covert brain infarcts in patients with acute non-cardioembolic ischemic stroke: PACIFIC-STROKE trial

Hart RG, et al. Eur Stroke J. 2025. Online ahead of print

Hart RG, Smith EE, Wang A, Mundl H, Colorado P, Joundi RA, Katsa,
READ
EMAIL

An external control arm for the oral factor XIa inhibitor asundexian phase 2 trial in atrial fibrillation (PACIFIC-AF) using electronic health records

Vaitsiakhovich T, et al. Cardiol Ther. 2025;14(3):403-421.

Vaitsiakhovich T, Hartenstein A, Privitera S, Patel MR, Piccini ,
READ
EMAIL

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial

Alexander JH, et al. JAMA Cardiol. 2025;10(6):555–563.

Alexander JH, Lydon EJ, Piccini JP, et al.,
READ
EMAIL

Dual versus single antiplatelet therapy in patients with non-cardioembolic acute ischemic stroke and baseline MRI

De Marchis GM, et al. Eur Stroke J. 2025;10(3):766-774.

De Marchis GM, Toebak A, Dittrich T, Vlachos D, Wang A, Smith EE,
READ
EMAIL

Phase 2 study of the factor XI antisense inhibitor IONIS-FXI(Rx) in patients with ESRD

Walsh M, et al. Kidney Int Rep. 2022;7(2):200-9.

Walsh M, Bethune C, Smyth A, Tyrwhitt J, Jung SW, Yu RZ, Wang Y,,
READ
EMAIL

Thromboembolic events in the hemodialysis setting: understanding risk profiles and cumulative incidences to inform clinical trial design

Karaboyas A, et al. J Am Heart Assoc. 2025;14(1):e033983.

Karaboyas A, Zhao J, Tanko LB, Joergensen KT, Pap AF, Dasgupta I,
READ
EMAIL

Effect of age, sex, renal impairment and hepatic impairment on the safety, pharmacokinetics and pharmacodynamics of asundexian

Brase C, et al. Clin Pharmacokinet. 2024;63(11):1631-1648.

Brase C, Schmitz S, Sommer K, Halabi A, Kanefendt F,
READ
EMAIL

Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy male East Asian volunteers: Results from two phase 1 studies

Dong Z, et al. Pharmacol Res Perspect. 2024;12(5):e70012.

Dong, Z., Hashizume, K., Friedrichs, F., Liu, P., Tanaka, T., & ,
READ
EMAIL

Asundexian versus apixaban in patients with atrial fibrillation

Piccini JP, et al. N Engl J Med. 2025;392(1):23-32.

Jonathan P Piccini, Manesh R Patel, Jan Steffel, Keith Ferdinand,
READ
EMAIL
Bayer logo

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

 

© 2026 Bayer. Bayer and the Bayer Cross are registered trademarks for Bayer.

Site last updated 01/2026